RegisterLogin

C6 Ceramide

CAT: 0804-HY-19542-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-19542-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects[1][2][3][4][5].
CAS Number
[124753-97-5]
Product Name Alternative
C6-Cer; N-Hexanoylsphingosine
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/c6-ceramide.html
Purity
99.82
Solubility
DMSO : ≥ 100 mg/mL
Smiles
CCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O
Molecular Formula
C24H47NO3
Molecular Weight
397.63
Precautions
H302, H315, H319, H335
References & Citations
[1]Zhu Q, et, al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011 Jan 27;2 (1) :e117. |[2]Liu L, et, al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020 Aug 3;18 (1) :298. |[3]Mitoma J, et al. Bipotential roles of ceramide in the growth of hippocampal neurons: promotion of cell survival and dendritic outgrowth in dose- and developmental stage-dependent manners. J Neurosci Res. 1998 Mar 15;51 (6) :712-22.|[4]Flowers M, et al. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Res Treat. 2012 Jun;133 (2) :447-58. |[5]Wilhelm R, et al. C6 Ceramide (d18:1/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma. Cancers (Basel) . 2021 Jan 13;13 (2) :270.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-139062-01C6 Urea Ceramide
HY-W356116C6 NBD Ceramide
HY-19542SCeramide C6-d7
HY-116609C6 L-threo Ceramide
HY-D1749C6 NBD L-threo-ceramide
HY-165087C6 Biotin ceramide (d18:1/6:0)
HY-116585C6 D-Threo Ceramide (d18:1/6:0)
HY-172666FC6 Biotin dihydro ceramide (d18:0/6:0)
HY-145517-01C6-Phytoceramide
HY-150978DDAO-C6

Alternative Products

CatalogName
C2777-89C24 Ceramide (Lignoceric Ceramide)
EU2633Ceramide (Ceramide) ELISA Kit
N3120Ceramide (NBD C6-Ceramide)
254918-01Ceramide
MBS7616743-01Rat Ceramide (Ceramide) ELISA Kit
YLA3997HU-01Human Ceramide (Ceramide) ELISA Kit
YP-W71758-01Porcine ceramide (ceramide) ELISA Kit
TBI1640-25MGC6 Ceramide, Cell permeable ceramide
MBS6074704-01C24:1 Ceramide (Nervonic Ceramide)
YLA1826MO-01Mouse Ceramide (Ceramide) ELISA Kit

Popular Products